---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Diagnosis"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Diagnosis. Topics: Office blood pressure measurement: standardized protocol, Out-of-office blood pressure: home and ambulatory monitoring, Out-of-office thresholds corresponding to office blood pressure, Pseudoresistance: confirmation of true treatment resistance, and 6 further topics. 10 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/diagnosis"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Office blood pressure measurement: standardized protocol

> “Accurate measurement of BP is essential to diagnose high BP, ascertain BP-related CVD risk, and assess response to therapy.”
> “Office BP should be based on the average of available readings, and an average of ≥2 BP measurements obtained on ≥2 separate occasions may minimize error and provide a more accurate estimation of office BP.”
> “Mean unattended AOBP is lower than mean office BP obtained with a clinician present and using a standardized protocol.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.5-2"></a>

### Out-of-office blood pressure: home and ambulatory monitoring

> “Out-of-office BP monitoring with either ABPM or HBPM provides valuable and distinct information compared with office BP for confirming the diagnosis of hypertension.”
> “ABPM is preferred for excluding white-coat hypertension and masked hypertension among individuals not taking antihypertensive medication.”
> “However, HBPM is preferred for excluding a white-coat effect and masked uncontrolled hypertension among individuals taking antihypertensive medication as ABPM is more difficult to conduct repeatedly in clinical practice.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “The USPSTF recommends obtaining blood pressure measurements outside of the clinical setting for diagnostic confirmation before starting treatment.”

Source: [US Preventive Services Task Force (2021)](https://jamanetwork.com/journals/jama/fullarticle/2779190)

<a id="topic-2.2.1.5-3"></a>

### Out-of-office thresholds corresponding to office blood pressure

| Office, mm Hg | HBPM, mm Hg | Daytime ABPM, mm Hg | Nighttime ABPM, mm Hg | 24-Hour ABPM, mm Hg |
| --- | --- | --- | --- | --- |
| “130/80” | “130/80” | “130/80” | “110/65” | “125/75” |
| “140/90” | “135/85” | “135/85” | “120/70” | “130/80” |

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.5-4"></a>

### Pseudoresistance: confirmation of true treatment resistance

> “Evaluation of resistant hypertension requires exclusion of pseudoresistance, including inaccurate BP measurement”
> “Routine measurement of out-of-office BP is an important component of resistant hypertension management as both home BP and 24-hour ABPM are shown to be superior to office BP in predicting cardiovascular events.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “Assessment for treatment adherence and use of ABPM (or home BP monitoring if ABPM is unavailable) are needed to confirm RH.”
> “Inaccurate measurement of BP can result in the appearance of treatment resistance.”
> “In this study of patients referred for RH, inaccurate BP measurement was estimated at 33%.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “In addition, excluding pseudo-resistance is a prerequisite.”
> “Specifically, pseudo-resistance indicates poor adherence to BP-lowering treatment, which should be verified by careful questioning of the patient in the first instance (Section 7.4.3).”
> “In addition, white-coat hypertension must be excluded.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.1.5-5"></a>

### White-coat effect in apparent treatment-resistant hypertension

> “A clinically significant white-coat effect may be present in 28% to 39% of individuals with aTRH by office BP measurement.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Among them, 8295 (12.2% of the database) had resistant hypertension (office blood pressure ≥140 and/or 90 mm Hg while being treated with ≥3 antihypertensive drugs, 1 of them being a diuretic).”
> “After ambulatory blood pressure monitoring, 62.5% of patients were classified as true resistant hypertensives, the remaining 37.5% having white-coat resistance.”

Source: [de la Sierra et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21444835/)

> “Therefore, it is reasonable to exclude a white-coat effect using out-of-office BP monitoring for individuals with apparent resistant hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.5-6"></a>

### Medication nonadherence: prevalence and adherence testing

> “Studies have documented that up to 50% of patients do not adhere to their antihypertensive medications after 1 year of treatment.”
> “Adherence to medications can be assessed in multiple ways, including self-report, medication adherence questionnaires, review of prescription refills, pill counting, electronic pill boxes, and chemical adherence testing of antihypertensive drug levels (Table 15).”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “From an initial discovery of 921 studies, we identified 24 studies that measured medication adherence for patients with uncontrolled BP despite being prescribed three or more antihypertensive medications of different classes.”
> “the pooled prevalence of nonadherence was 31.2%”
> “with nonadherence rates ranging from 3.3 to 86.1%.”
> “The strongest contributor to variance in nonadherence rates was the method of adherence assessment used.”

Source: [Durand et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28777133/)

> “There is no gold standard for measuring adherence.”
> “A direct method such as urine or blood measurement of drug or metabolites is considered more robust but is relatively expensive, is of limited availability, and does not perfectly reflect level of adherence.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Objective evaluation of adherence (either directly observed treatment or detecting prescribed drugs in blood or urine samples) should also be considered, if resources allow.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.1.5-7"></a>

### Primary aldosteronism screening: 2025 Endocrine Society guideline

> “We suggest that all individuals with hypertension be screened for PA by measuring aldosterone and renin and determining the aldosterone to renin ratio, and that subsequent clinical care be guided by the results.”

Source: [Adler et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40658480/)

> “the 2025 Endocrine Society guideline extends screening recommendations beyond high-risk subgroups to encompass all adults with hypertension, issuing a conditional (Grade 2) recommendation.”
> “Specifically, a positive screen is defined by a suppressed renin – plasma renin activity (PRA) ≤1 ng/mL/h or direct renin concentration (DRC) ≤8.2 mU/L – in combination with inappropriately elevated aldosterone (≥10 ng/dL by immunoassay or ≥7.5 ng/dL by liquid chromatography), and an elevated ARR (aldosterone [ng/dL] to PRA [ng/mL/h] ratio >20 or aldosterone [pmol/L] to DRC [mU/L] ratio >70).”

Source: [Owei et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12885222/)

<a id="topic-2.2.1.5-8"></a>

### Primary aldosteronism screening: 2025 AHA/ACC guideline

> “In adults with resistant hypertension, screening for primary aldosteronism is recommended regardless of whether hypokalemia is present to increase rates of detection, diagnosis, and specific targeted therapy.”
> “Patients with primary aldosteronism typically have suppressed renin activity (<1 ng/mL/h).”
> “The most commonly used cutoff value for the aldosterone to renin activity ratio is 30 when plasma aldosterone concentration is reported in nanograms per deciliter (ng/dL) and plasma renin activity in nanograms per milliliter per hour (ng/mL/h), although some data support alternative thresholds (20 or 40).”
> “Initial screening for primary aldosteronism can typically be interpreted in the context of most medications that affect renin and aldosterone.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.5-9"></a>

### Primary aldosteronism screening: sensitivity of the aldosterone-to-renin ratio

> “The aldosterone–renin ratio had poor sensitivity and negative predictive value for detecting biochemically overt primary aldosteronism.”

Source: [Brown et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7459427/)

<a id="topic-2.2.1.5-10"></a>

### Primary aldosteronism screening rates in practice

> “However, the rate of screening for primary aldosteronism in guideline-recommended individuals is <2% in the United States.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “After a median follow-up of 3.3 years (IQR, 1.0 to 6.7 years) after meeting criteria for apparent treatment-resistant hypertension, 4277 (1.6%) patients had testing for primary aldosteronism.”

Source: [Cohen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7965294/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
